Japan Lifeline sees strong Q2 growth, maintains full-year forecast

For the six months ended September 30, 2025, Japan Lifeline reported net sales of 29,285 million yen, up 4.6% year-over-year. Operating profit increased by 5.7% to 6,620 million yen, with ordinary profit rising 7.4% to 6,624 million yen. Net income attributable to owners of the parent grew 7.7% to 4,774 million yen. This strong performance was primarily fueled by EP/Ablation and Cardiovascular segments, which saw sales increase by 4.1% and 5.0% respectively. Neurovascular sales surged by 48.4%, and Gastrointestinal sales rose by 15.7%.

Despite the positive first-half results, the company maintained its full-year consolidated earnings forecast for the fiscal year ending March 31, 2026, projecting net sales of 59,300 million yen and net income attributable to owners of the parent of 9,350 million yen. The company cited steady progress in line with initial guidance, with EP/Ablation and core products exceeding expectations despite slower progress in Cardiac Rhythm Management and Gastrointestinal segments.

Total assets as of September 30, 2025, increased to 75,274 million yen, up 151 million yen from the previous fiscal year-end. Net assets also grew by 1,063 million yen to 60,977 million yen. The company announced a second-quarter dividend of 0.00 yen and a full-year forecast of 54.00 yen, unchanged from its last announcement.